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Validating a novel index (SWAT-Bp) to predict mortality 
risk of community-acquired pneumonia in Malawi
ORIGINAL RESEARCH
Abstract
Background
Community-acquired pneumonia is a major cause of  mortality worldwide. Early assessment and initiation of  management improves 
outcomes. In higher-income countries, scores assist in predicting mortality from pneumonia. These have not been validated for use in 
most lower-income countries. 
Aim
To validate a new score, the SWAT-Bp score, in predicting mortality risk of  clinical community-acquired pneumonia amongst hospital 
admissions at Queen Elizabeth Central Hospital, Blantyre, Malawi.
Methods
The five variables constituting the SWAT-Bp score (male [S]ex, muscle [W]asting, non-[A]mbulatory, [T]emperature (>38oC or <35oC) 
and [B]lood [p]ressure (systolic<100 and/or diastolic<60)) were recorded for all patients with clinical presentation of  a lower respiratory 
tract infection, presumed to be pneumonia, over four months (N=216). The sensitivity and specificity of  the score were calculated to 
determine accuracy of  predicting mortality risk. 
Results
Median age was 35 years, HIV prevalence was 84.2% amongst known statuses, and mortality rate was 12.5%. Mortality for scores 0-5 
was 0%, 8.5%, 12.7%, 19.0%, 28.6%, 100% respectively. Patients were stratified into three mortality risk groups dependent on their 
score. SWAT-Bp had moderate discriminatory power overall (AUROC 0.744). A SWAT-Bp score of  ≥2 was 82% sensitive and 51% 
specific for predicting mortality, thereby assisting in identifying individuals with a lower mortality risk.
Conclusion
In this validation cohort, the SWAT-Bp score has not performed as well as in the derivation cohort. However, it could potentially assist 
clinicians identifying low-risk patients, enabling rapid prioritisation of  treatment in a low-resource setting, as it helps contribute towards 
individual patient risk stratification.
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Introduction
Lower respiratory tract infections (LRTIs) are the fourth most 
common cause of  death globally, responsible for 3.1 million 
deaths annually, and remain the leading cause of  death in 
low-income countries1. Pneumonia (LRTI with radiological 
evidence) accounts for 14% of  deaths in Malawi2. At Queen 
Elizabeth Central Hospital (QECH), Blantyre, Malawi, there 
are approximately 1500 pneumonia admissions annually, 
with 20% in-patient mortality rate3, similar to other sub-
Saharan countries4. Effective management relies upon 
rapid assessment, diagnosis and treatment. Accurate early 
assessment of  disease severity is essential to patient triage5-7. 
Determining the need for hospital admission is medically and 
economically important, and initial assessment influences 
subsequent management decisions8,9. Clinical assessment of  
pneumonia frequently fails to accurately estimate the risk of  
clinical deterioration10-12. Severity scores provide a structured 
and objective severity assessment, and can improve the 
identification of  high and low risk patients13,14.
Widely-used severity scores include the CURB-65 and CRB-
65 scores10,15,16 and the pneumonia severity index (PSI)12. 
These have been validated in many countries including 
Canada, New Zealand, Spain and Pakistan5,10,17,18. However, 
their application in areas of  high HIV prevalence, specifically 
sub-Saharan Africa, is not well studied. Indeed, the eligibility 
criteria for these scores exclude patients with HIV infection12,16. 
Birkhamshaw et al. showed that the sensitivity of  the CRB-
65 score in a Malawian hospital for a score of  ≥2 was low 
(36.4%) compared to the UK (76.8%)16,19. This renders the 
CRB-65 score insensitive at predicting pneumonia mortality 
risk in this setting20. Birkhamshaw et al. proposed a novel 
score (SWAT-Bp) incorporating five variables independently 
associated with disease19. The constituent variables are: male 
[S]ex; muscle [W]asting; non-[A]mbulatory; [T]emperature 
(>38oC or <35oC); [B]lood [p]ressure (Systolic Pressure<100 
and/or Diastolic Pressure<60). Mortality was positively 
correlated with overall score. We present prospective data 
from Malawi against which the SWAT-Bp score is validated. 
The aim was to describe the sensitivity and specificity of  the 
score in a validation cohort.
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Methods
The prospective cohort study was conducted on the medical 
wards of  Queen Elizabeth Central Hospital. This 1,000-
bed government hospital in Blantyre, Malawi, has typical 
staff  ratios of  1 nurse to 50 patients. We approached all 
consecutive adults (≥16 years) admitted between 19th 
February and 1st April or 6th October and 27th November 
2011, with a preliminary clinical diagnosis of  community-
acquired pneumonia. Patients were included if  they had 
a clinical presentation of  LRTI and a presumed primary 
diagnosis of  CAP on admission in accordance with the British 
Thoracic Society primary care guidelines: (1) symptoms 
of  acute lower respiratory tract illness, (2) new focal chest 
signs on examination, (3) evidence of  systemic illness, (4) no 
other explanation for the illness and (5) a clinical decision 
that it should be treated with antibiotics.21Exclusion criteria 
were: (1) alternative primary admission diagnosis [not CAP], 
(2) hospitalisation within the preceding 14 days (excluding 
hospital-acquired pneumonia), (3) pneumonia as an expected 
terminal event in disseminated Kaposi’s sarcoma, and (4) 
symptoms for more than 21 days. Ethical approval was 
obtained from the University of  Birmingham BMedSc 
Population Sciences and Humanities Internal Ethics 
Committee, UK, and the College of  Medicine Research and 
Ethics Committee, Blantyre, Malawi. 
Data collection
Eligibility was confirmed from patient notes within 48 hours 
of  admission. The first recorded temperature and blood 
pressure were used to derive the score. The other variables 
were measured on enrolment, within 48 hours of  admission. 
Muscle wasting was defined as mid-upper arm circumference 
(MUAC) ≤190mm22 and non-ambulatory was defined as 
‘unable to walk unaided’. The MUAC was measured for 
each patient during enrolment and the ambulatory status 
by verbal confirmation from the participant or relative (if  
not documented). Paper based data records were pseudo-
anonymised using study numbers for confidentiality. 
Figure 1: Flow-chart demonstrating the screening and follow-up of 
study participants
Participants 
included in 
analysis
Participants lost to 
follow-up Comparison
N % N % Test Value P-value*
Total cohort 216 100 18 100 - - -
Male 90 41.7 10 55.6 χ² 1.3 0.25
In-hospital Mortalities 27 12.5 - - - - -
HIV positive (% of known) 144 84.2 10 90.9 χ² 0.36 0.55
HIV unknown 45 20.8 7 38.9 χ² 3.1 0.078
Median admission (days) 6 - - - - - -
Median age (years) 35 - 32 - Independent Samples Median 2.96 0.086
Age 16-24 35 16.2 2 11.1
- - -
Age 25-34 67 31.0 11 61.1
Age 35-44 66 30.5 3 16.7
Age 45-54 21 9.7 1 5.6
Age 55+ 27 12.5 1 5.6
SWAT-Bp score
0 43 19.9 2 11.1
- - -
1 59 27.3 6 33.3
2 55 25.5 5 27.8
3 42 19.4 4 22.2
4 14 6.5 0 0
5 3 1.4 1 5.6
Table 1: Characteristics of participants included in the analysis and those lost to follow-up. Statistical comparisons were made.
* P-value of  <0.05 is statistically significant, 
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Patient outcomes were established by daily review and a 
triangulation of  data from ward discharge books, electronic 
discharge system and paper records office. For analysis, 
patients were classified as ‘alive at discharge’ or ‘died in-
hospital’. Those with indeterminable outcomes were 
excluded from the analysis and deemed lost to follow-up. 
Inpatients were followed up for a maximum of  30 days or 
discharge, whichever was sooner. Clinicians treating the 
patients were not involved in this research study. Hence, they 
were blinded to the scoring system, and this would not have 
impacted patient management.
Statistical analyses
We estimated that from a population of  200 patients, 
validation of  sensitivity would be possible to within 7% and 
specificity to within 8.3%, assuming 80% sensitivity and 75% 
specificity16,23. Odds ratios of  inpatient death were calculated 
for each variable in the SWAT-Bp score. Sensitivity, specificity, 
positive predictive values (PPV), negative predictive values 
(NPV) and area under the receiving operating characteristic 
(ROC) curve were calculated using PASW Statistics 17 
manufactured by IBM.
Results
Between 19th February – 1st April and 6th October – 27th 
November 2011, 234 patients with a preliminary diagnosis 
of  community-acquired pneumonia met the eligibility criteria 
(Figure 1). Of  these, 18(7.7%) were excluded due to loss to 
follow-up.  Of  the 216 remaining participants included, 90 
(41.7%) were male. Mean age was 37 years (median 35, range 
16-79). HIV status was unknown for 45 patients (20.8%); 
144 were HIV positive (84.2% of  known HIV status). 
Overall inpatient mortality rate was 12.5% (27); 48% (13) of  
these deaths occurred within 48 hours and 70% (19) within 
one week of  admission. Baseline characteristics were similar 
between included participants and those lost to follow-up 
(Table 1).
The SWAT-Bp score of  ≥2 demonstrates a sensitivity of  
81.5% (95% CI 61.3-93.0) and specificity of  51.3% (95% CI 
44.0-58.6). The SWAT-Bp score could further divide patients 
into three groups; 47% of  participants score 0 or 1 with 4.9% 
mortality, 26% of  participants score 2 with 12.7% mortality 
and 27% score 3 or above with 25.4% mortality. The 
moderate performance of  the SWAT-Bp score in predicting 
mortality risk is demonstrated by the area under the ROC 
curve of  0.744. The most significant predictors for mortality 
were male sex (Odds Ratio 4.0) and being non-ambulatory 
(Odds Ratio 4.1) (Table 4). For these variables, sensitivity and 
specificity were 70.4% and 62.4% respectively for male sex 
and 66.7% and 67.2% for non-ambulatory status. Negative 
predictive value was 93.7% and 93.4% respectively (Table 3).
PPV = Positive predictive value; NPV = Negative predictive value
Figure 3 demonstrates how the SWAT-Bp score could be 
used in clinical practice to help to stratify the mortality risk 
of  patients attending hospital with clinical presentation of  
a lower respiratory tract infection and a presumed primary 
diagnosis of  pneumonia.
Table 2: Relationship between the SWAT-Bp score and risk of 
mortality
SWAT-Bp 
Score
Patients N Mortalities
 N (%)
95% Confidence Intervals (CI)
Lower Upper
0 43 0 (0) 0 8.2
1 59 5 (8.5) 3.7 18.3
2 55 7 (12.7) 6.3 24.0
3 42 8 (19.0) 10.0 33.3
4 14 4 (28.6) 11.7 54.6
5 3 3 (100) 43.8 100
Figure 2: Graphic representation of the relationship between SWAT-
Bp score and inhospital mortality
Table 3: Test characteristics for mortality prediction for the SWAT-
Bp score
SWAT-Bp cut-off 
point
Sensitivity % 
(95% CI)
Specificity % 
(95% CI)
PPV %
(95% CI)
NPV %
(95% CI)
≥0 100 (84.5-100) 0 (0-2.5) 12.5 (8.5-17.8) -
≥1 100 (84.5-100) 22.8 (17.1-30.0) 15.6 (10.7-22.1) 100 (89.8-100)
≥2 81.5 (61.3-93.0) 51.3 (44.0-58.6) 19.3 (12.7-28.0) 95.1 (88.4-98.2)
≥3 55.6 (35.6-74.0) 76.7 (70.0-82.4) 25.4 (15.4-38.7) 92.4 (86.7-95.8)
≥4 25.9 (11.9-46.6) 94.7 (90.2-97.3) 41.2 (19.4-66.5) 89.9 (84.7-93.6)
5 11.1 (2.9-30.3) 100 (97.5-100) 100 (31.0-100) 88.7 (83.5-92.5)
Gender 70.4 (49.7-85.5) 62.4 (55.1-69.3) 21.1 (13.5-31.2) 93.7 (87.5-97.0)
Non-ambulatory 66.7 (46.0-82.8) 67.2 (60.0-73.7) 22.5 (14.2-33.5) 93.4 (87.4-96.7)
Table 4: Individual predictor variables in the SWAT-Bp score 
separated by number of patients scoring for that variable, number 
of mortalities and Odds Ratios
Individual SWAT-Bp 
Variables
Patients 
scoring N
Mortalities 
N (%)
Odds Ratio 
(OR)
95% 
Confidence 
Intervals
Lower Upper
Gender 90 19 (21.1) 4.0 1.6 9.5
Muscle wasting 39 9 (23.1) 2.7 1.1 6.5
Ambulatory status 80 18 (22.5) 4.1 1.7 9.6
Temperature 90 15 (16.7) 1.6 0.7 3.6
Blood Pressure 67 13 (19.4) 2.7 1.2 6.1
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Figure 3: The SWAT-Bp score is a severity assessment tool based 
on five adverse clinical features, for use in a hospital setting. This 
one-step strategy enables stratification of patients with community-
acquired pneumonia into groups according to their risk of mortality.
Discussion 
This study validates the novel SWAT-Bp score which could 
be used to stratify patients into three risk groups.19 A SWAT-
Bp score of  0 or 1 indicates milder clinical pneumonia with 
4.9% chance of  mortality (2.2% in derivation cohort), likely 
suitable for outpatient management or early discharge from 
hospital. A score of  2 indicates moderate pneumonia with 
12.7% mortality risk (7.4% in derivation), requiring hospital 
admission and management. Scoring ≥3 indicates severe 
pneumonia with one in four patients dying in-hospital (one 
in two in derivation), necessitating immediate hospitalisation 
and appropriate management. The objective variables of  
which the score consists are easily assessed on admission, 
enabling rapid triage in busy clinical settings and reducing 
bias, while requiring little training to administer. Differences 
in mortality risks from the derivation cohorts could be due 
to numerous factors including seasonal variation, variation in 
microbiological patterns and change in resources over time. 
Alternatives include patients lost to follow-up differing from 
the patients included, but these options are all speculative 
and therefore no definitive conclusions can be drawn. This 
study is conducted on in-patients and hence suggests that 
approximately half  this population could be suitable for 
outpatient management or early discharge (those scoring 
0 or 1). A reduction of  this magnitude would be clinically 
and economically useful. Although the NPV for a score of  
0 or 1 indicates that approximately 95% of  these patients 
would survive, evidently, discharging all these patients with 
a one in 20 mortality risk would be perilous. It is important 
to highlight that this score is designed for pragmatic use 
during assessment in combination with clinical judgement. 
Reflecting on these statistics, one can further differentiate 
the management of  the lower mortality risk scores. A score 
of  0 correlates to 0% mortality risk indicating outpatient 
management may be appropriate. A score of  1 indicates 
a relatively low risk of  mortality, where caution should be 
heeded with discharge counselling used to facilitate early 
discharge. However, this score has not been validated for 
outpatient use and our data collection did not focus on 
individual management of  patients whilst hospital inpatients. 
We can, therefore, not assume that these patients could 
all have been managed as outpatients as we do not know 
whether their survival was in part associated with provision 
of  medical management that is unavailable in the community, 
such as oxygen therapy or intravenous antibiotics.
The sensitivity of  a SWAT-Bp score of  ≥2 (81.5%) indicates 
that this score aids in identification of  patients at lower risk 
of  deterioration. Practically speaking, if  patients with a score 
of  ≥2 deteriorate, they would already be in an appropriate 
setting in which higher level treatment may be available. The 
SWAT-Bp score stratifies patients with clinical pneumonia 
according to mortality risk, demonstrated by an AUROC 
of  0.744 in this study, and 0.867 in the derivation study.19 In 
the original validation cohort of  the CURB-65 and CRB-65 
scores, comparatively slightly better values were obtained for 
sensitivity (75% and 80% respectively) and specificity (75% 
and 61%), as well as the AUROC for the CURB-65 (0.79) and 
CRB-65 (0.76) scores.16 The CURB-65 and CRB-65 scores 
are widely used in higher-income countries, where there is 
much evidence supporting their accuracy.10,12,16,17 Despite 
recommendations that they should be revalidated for use in 
novel environments, few such studies have been reported. 
One study in Nigeria demonstrated strong sensitivity and 
specificity of  the CURB-65 score, but the sample size was 
small (80) and HIV prevalence was low (14.3% amongst 
those with known status; a high proportion did not undergo 
HIV testing).24 Conflicting evidence exists regarding whether 
pneumonia in HIV-infected patients differs from HIV-
negative individuals, in terms of  clinical presentation and 
outcome.25-28 Therefore, it may be inappropriate to apply 
these scores to assess pneumonia severity in Malawi, where 
approximately 11% of  adults in the community29 and 80% 
of  those presenting to hospital with CAP19 are infected 
with HIV. The CRB-65 score was found to be less sensitive 
(sensitivity 36.4%, specificity 80.6%, AUC 0.649) in stratifying 
patients presenting with LRTI suggestive of  pneumonia in 
Malawi than the SWAT-Bp score.19 Patients with pneumonia 
in Malawi are younger; the average life expectancy is 58 years 
compared to 80 in the UK.2,29  Simple, rapid pneumonia 
severity assessment tools are needed which perform well in 
regions of  high HIV rates and few resources. A recent study 
in Uganda derived a new four-point score for stratification 
of  mortality risk among HIV-infected individuals with 
pneumonia. It consisted of  tachycardia, tachypnoea, hypoxia 
and CD4 count <50cells/mm3 and stratified patients with 
incremental mortality risk.30 This score required limited 
laboratory data but only included patients who were HIV 
positive which is unlikely to be pragmatic.
The most significant variables from the SWAT-Bp score in 
predicting mortality risk are simple objective measures: males 
(OR 4.0) and non-ambulatory status (OR 4.1). Ambulatory 
(NPV 93.4%) and female (NPV 93.7%) patients appear to 
be less likely to die from pneumonia in this study population. 
Sex disparity has been demonstrated amongst tuberculosis 
patients in South Africa; a smaller proportion of  female 
subjects provided smear-positive sputum samples than 
males. This was attributed to a higher index of  suspicion in 
females and delays in health-seeking behaviours in males.31 
Additionally, male sex has previously been demonstrated 
as an independent risk factor for severe sepsis in Malawi.32 
We cannot be certain if  our study findings reflect increased 
*defined as mid-upper arm circumference (MUAC) ≤190mm
† We are 95% certain that the mortality risk for a score of  <2 is between 
2.1% and 11.0%
Ŧ We are 95% certain that the mortality risk for a score of  2 is between 
6.3% and 24.0%
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female health-seeking behaviours or whether the most unwell 
females never attend hospital. However, it is also worth 
noting that the most significant variables in the validation 
cohort differed from the derivation cohort, making it 
difficult to draw precise conclusions about the importance 
of  each individual variable in the composite score.
Strengths and limitations
Strengths of  this study include the prospective design and 
hence inclusion of  all patients with a primary diagnosis of  
pneumonia on admission, despite only 127 (63.2% of  known 
discharge diagnoses) having a diagnosis of  pneumonia at 
end-point. The inclusion of  these patients is pragmatic and 
represents widespread practice in resource-limited settings. 
Evidently, it is clinically challenging to correctly diagnose 
pneumonia on admission, as demonstrated by a study 
in Uganda where only 9.6% of  patients presenting with 
clinical pneumonia were confirmed bacterial pneumonia 
on discharge. Pulmonary tuberculosis accounted for over 
half  of  the incorrect pneumonia admission diagnoses.30 
Additionally, by incorporating two separate data collection 
periods at different times throughout the year could help 
adjust for seasonality changes; it would be better to conduct 
data collection over an entire year to ensure more complete 
adjustment for this factor. To our knowledge, this is the 
only severity assessment score for pneumonia that has been 
derived and validated with two separate cohorts from a 
resource-limited setting with high HIV rates, rendering it a 
useful contribution to current research.
However, this study was primarily limited by the relatively 
small sample size (and hence small number of  deaths) in 
addition to the limitation of  being a single centre trial. This 
perhaps enables scope for revalidation in other centres in 
sub-Saharan Africa. The international definition of  CAP 
is an acute infection of  pulmonary parenchyma with acute 
infiltrate demonstrated on chest x-ray.16,33 In this setting, 
universal radiological confirmation was prevented by 
resource limitations, especially portable radiographs for the 
most unwell patients. Our loss to follow-up rate of  7.5% 
reflects limitations in clinical data collection, incomplete 
patient records systems and complicated patient flow. These 
factors feed into wider than envisaged confidence intervals 
(61-93% for sensitivity and 44-58% for specificity at a score 
of  ≥2). Baseline characteristics were similar in those lost 
to follow-up and those included. The incorporation of  
community follow-up in future research would be beneficial 
to determine outcomes for discharged patients and enable 
validation of  the score in an outpatient setting.
Conclusion
The SWAT-Bp score has been validated in a new population 
sample to predict mortality risk from clinical community-
acquired pneumonia on admission to hospital in Malawi. It 
could be used as an adjunct to stratify patients with pneumonia 
into low, intermediate and high risk mortality groups, thereby 
aiding management decisions. It could be most useful in 
identification of  lower-risk patients who may be suitable for 
early discharge or outpatient treatment. However, the score 
did not perform as well as in the derivation cohort. 
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